AIM: To identify the effective and safety of ranibizumab intravitreal injection in patients with macular edema(ME)caused by diabetic macular(DM)and retinal vein obstruction(RVO).

METHODS: Thirty-eight eyes of thirty-five patients was retrospectively evaluated, twenty-three with ME caused by DM and fifteen with RVO, who received intravitreal ranibizumab(0.5mg/0.05ml)and were followed up for at least a month., The best corrected visual acuity(BCVA), central retinal thickness(CRT)and intraocular pressure(IOP)were followed up at 1, 3d, 1wk and 1mo respectively. The effect of the DME and RVO-ME were compared.

RESULTS: DME and RVO- ME group after treatment in 1, 3d, 1wk, the BCVA were obviously improved, and the differences were statistically significant(P<0.05). But compared the BCVA in 1mo with before showed no statistically significant difference(P>0.05). DME and RVO-ME group after treatment in 1, 3d, 1wk and 1mo, CRT was obviously improved, and the differences were statistically significant(P<0.05). The BCVA and CRT of treatment showed no statistically significant difference between DME with RVO-ME(P>0.05).

CONCLUSION: Bevacizumab intravitreal injection for ME caused by DM and RVO was safe and effective.